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aResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades,
Universitat Internacional de Catalunya, Barcelona, Spain
bCognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute, IDIBELL, Spain
cInternational Corporate Affairs, Alzheimer’s Disease, Eli Lilly and Co
Accepted 11 January 2018
Abstract. Alzheimer’s disease (AD) research is at a critical time. The global society is increasingly aware of the frightening
rate of growth of the human and financial burden caused by this condition and of the urgent need to halt its progression.
Consequently, the scientific community holds great responsibility to quickly put in place and optimize the machinery necessary
for testing new treatments or interventions. In this context demand for participants for AD research is at an all-time high. In this
review, we will focus on a methodological factor that is increasingly recognized as a key factor that shapes trial populations
and affects validity of results in clinical trials: patient engagement, recruitment, and retention. We outline specific problems
relevant to patient engagement in AD including recruiting enough participants, difficulties in participant retention, ensuring
the recruited sample is representative of the general AD population, the burden of screening failures, and new challenges
related to recruiting in preclinical disease. To address the urgent need for more research studying the applicability and cost-
effectiveness of different recruitment strategies across different settings and nationalities, we describe the Models of Patient
Engagement for Alzheimer’s Disease (MOPEAD) project, a public-private partnership promoted by the Innovative Medicine
Initiative (IMI), which will provide a large multinational quantitative analysis comparing different innovative recruitment
models. We also discuss strategies that address each problem and draw on the experience of Fundació ACE to argue that
focusing resources on comprehensive AD centers that offer coordinated clinical and social care and participate in basic and
clinical research, is an effective and efficient way of implementing many of the discussed strategies.
Keywords: Alzheimer’s disease, clinical trials, community outreach, Fundació ACE, MOPEAD, patient engagement,
recruitment, retention
INTRODUCTION
Global Alzheimer’s disease (AD) research is at
a critical time. AD is the first cause of dementia
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worldwide. The 2015 World Alzheimer Report esti-
mates that the 46.8 million people worldwide living
with dementia will almost double every 20 years [1].
The global society is increasingly aware of the fright-
ening rate of growth of the human and financial burden
caused by this condition, increasing from 604 bil-
lion in 2010 to 818 billion US$ in 2015, and of the
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urgent need to halt its progression. In the wake of
this increased sense of urgency, society is calling
for increased action and governments worldwide are
respondingbyrecognizingdementiaasapublichealth
priority and drafting national plans that increase fund-
ing and define strategies to defeat AD [2, 3].
Consequently, the scientific community holds
great responsibility to quickly put in place and
optimize the machinery necessary for testing new
treatments or interventions. Of the many method-
ological factors that can be improved in AD trials,
we will focus on patient engagement, recruitment,
and retention. This issue has perhaps garnered less
attention than other topics such as study design,
establishing effective outcome measures, or incorpo-
rating biomarkers but it is increasingly recognized
as a key factor that shapes trial populations and
affects validity of results [4, 5]. The demand for
participants for AD research is at an all-time high.
Data from the Alzheimer’s Association trial match
service [6] shows there are more than 250 studies
currently looking for volunteers. A recent editorial
warns that patient recruitment is the most impor-
tant rate limiting factor delaying therapy development
and is poised to derail the first goal of the National
Plan to Address Alzheimer’s Disease: to prevent and
effectively treat Alzheimer’s Disease by 2025 [7].
It describes a meeting in which key stakeholders
including the Alzheimer’s association, academics,
government agencies, and industry outlined an action
plan to address this problem. Another recent report
from the EU/US task force noted that AD research is
faced with unreasonably long periods of recruitment,
small proportion of patients recruited per center,
and unacceptably high drop-out rates and called for
increased research focused on understanding why
patients choose or refuse to participate and quanti-
fying the impact of different inclusion criteria and
strategies on recruitment [8].
In the following pages, we will outline spe-
cific problems relevant to patient engagement in
AD (Table 1) including recruiting enough partici-
pants, difficulties in participant retention, ensuring
the recruited sample is representative of the general
AD population, the burden of screening failures, and
new challenges related to recruiting in preclinical dis-
ease. We will also discuss strategies (Table 1) that
address each problem and draw on the experience of
Fundació ACE [9] to argue that focusing resources
on comprehensive AD centers that offer coordinated
clinical and social care and participate in basic and
clinical research, is an effective and efficient way
of implementing many of the discussed strategies.
Fundació ACE Institut Catala de Neurociences Apli-
cades, herein after ACE, has developed an integrated
multidisciplinary care model in Barcelona (Spain)
following the guidelines of the “Catalan Model for
Cognitive and Behavioral Disorders in Social Health
Care [10]” that includes diagnosis, therapy, follow-
up care, daycare, and a day hospital in the context of
an active research program. Since its start in 1996 up
to 2016, ACE has performed 21737 diagnoses, eval-
uated 17642 families, and participated in 128 phase
I, II, and III clinical trials.
INCREASING THE NUMBERS OF
POTENTIAL PARTICIPANTS
The first challenge is increasing the pool of poten-
tial participants. The demand for participants in AD
research is at an all-time high. Based on data from
clinicaltrials.gov, the National Institute on Aging
(NIA, USA) counted more than 150 open studies call-
ing for more than 70,000 participants which could
require screening of more than 700,000 potential
volunteers [11]. Furthermore, the recent trend of
focusing efforts in preclinical and prodromal AD will
require more subjects and longer follow-up time to
demonstrate treatment effects [12]. Low trial aware-
ness and unfavorable attitudes toward participation
are factors that negatively influence recruitment
which affect patients, referring doctors, and the soci-
ety at large. Studies in the US [13] and Europe
(IMPACT study, [14]) suggest that the majority of pri-
mary care doctors are not aware of AD trials in their
area. Patients and families generally depend on their
health care providers for information about available
clinical studies and doctors who are not specialized
in cognitive disorders or aging may understandably
not be aware of all the studies recruiting in their
area. Reports suggest that willingness to participate
depend more on attitudes toward research than care-
giver burden [15–17]. Specific concerns regarding the
potential harm of treatments and diagnostic tests, the
logistical and time consuming burden, or the futil-
ity of participation can cause unfavorable attitudes
toward participation in patients, care-givers and doc-
tors alike [14, 18–20]. Primary care physicians also
cite lack of time and availability of appropriate diag-
nostic tools to screen for cognitive impairment as
significant barriers to referral to AD studies. These
factors probably also contribute to poor detection of
cognitive impairment in primary care settings, 20%
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Table 1
Problems and remedial strategies in patient engagement for AD research
Problems and remedial strategies in patient engagement for AD research
Increasing the pool of potential participants
*Increase awareness and improve attitudes towards research via advertising, education, and community outreach campaigns.
*Maximize referrals through coordination with primary care and other local medical centers and establishment of best practice
guidelines for screening for cognitive impairment.
*Increase potential pool of participants by expansion and coordination of existing participant registries.
*Increase the number of recruited subjects by expanding the number of recruiting sites.
Improving participant retention
*Target outreach and adapt trials to the needs of care-givers, especially non-spousal care-givers.
*Make participation more rewarding and foster a sense of purpose by improving communication and giving regular feedback to
participants.
*Evaluation of patients’ social circumstances and support resources to direct them to appropriate studies and trials.
*Establish a relationship of trust through integrated and continued clinical and social care.
Ensuring representativeness of the recruited sample
*Implementation of community based participatory research methodology.
*Combining community outreach with increasing recruitment efforts in “satellite clinics” which primarily attend minority populations
generally due to their geographical location.
The burden of screen failures
*Ensure availability of appropriate diagnostic tests and clinical expertise in the recruiting center by:
*Recruiting from the same center where patients are diagnosed and followed
*Recruiting at centers that participate in basic and clinical research programs
Recruiting for prevention trials
*Requires far-reaching strategies that act upon multiple levels to engage a primarily non-memory clinic population.
*Large informative campaigns directed at the general public explaining the urgency of halting AD’s progression and the importance of
early diagnosis and research to achieve this goal.
*Innovative initiatives that facilitate the arrival of cognitively intact individuals to memory clinics (such as the Open House Initiative).
*Existence of registries of cognitively healthy individuals who are potentially willing to participate in research studies.
*Existence of observational cohorts with available biomarker data in which participants are asked upon entry about their willingness to
enroll in clinical trials in the case of positivity.
of dementia and 60% of MCI cases by some reports
[21]. Finally, due to a combination of restrictive
inclusion criteria (age restrictions, minimum MMSE
score, level of education, requirement of a study part-
ner, etc.) and elevated prevalence of comorbidity and
poly-pharmacy, a surprisingly small proportion of
AD patients are actually eligible for trials, 27% and
10–13% of AD patients from research [22] and clin-
ical [23, 24] settings, respectively.
Expanding the number of recruiting sites could be
a forthright way of increasing recruitment; however,
there is insufficient evidence to direct its implementa-
tion. Studies recruiting from multi-national sites face
difficulties derived from differences in patient pop-
ulations, cultural practices, and regulatory agencies
[5] and existing research suggests there are signifi-
cant differences in patient sample characteristics and
efficiency depending on the setting (memory clinic
versus community [37–39]) or nature (academic ver-
sus commercial [40, 41]) of the recruiting center.
We need more studies that compare the success and
cost-effectiveness of recruiting from different sites
including memory clinics, primary care centers, res-
idential homes, and other non-traditional settings
such as community centers, or web-based portals.
These gaps in knowledge motivated the design of
the Models of Patient Engagement for Alzheimer’s
Disease (MOPEAD) study [42]. Its objective is to
understand the obstacles to early diagnosis and treat-
ment faced by AD patients in various European
communities and to develop and evaluate innovative
models to overcome them. MOPEAD is a multina-
tional European public-private partnership promoted
by the Innovative Medicine Initiative (IMI) and
the European Federation of Pharmaceutical Indus-
tries and Associations (EFPIA) that will be carried
out by 14 partners including academic centers and
industry. Four screening models will be tested simul-
taneously in five European countries to evaluate
cost-effectiveness for identifying subjects with early
AD in community settings with different cultural and
socioeconomic conditions. The screening models that
will be evaluated include online cognitive testing pre-
ceded by an online marketing campaign, a memory
clinic evaluation preceded by a publicity campaign
(Open house model [37]), primary care physician
screening based on short cognitive tests and demen-
tia risk score calculation [43], and a similar screening
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procedure undertaken at a specialist outpatient clinic
where subjects present elevated risk of dementia: a
diabetes clinic in a tertiary care center.
Coordination with primary care and other local
medical centers is essential for maximizing refer-
rals. ACE has a contract with the Health Ministry
of the Government of Catalonia designating it as a
referral center for evaluating cognitive impairment
that supports referrals from the districts of greater
Barcelona. ACE has received 7,327 new referrals
since 2013. Evidence supporting screening for cog-
nitive impairment in the general population is still
inadequate [34]; however, publication of best prac-
tice guidelines regarding when and how to screen
for cognitive impairment or when to refer to the
nearest memory clinic could be of great help to pri-
mary care and other non-dementia specialists. The
professionals at ACE have contributed to best prac-
tice guidelines of dementia care [35] and perform
teaching activities at primary care centers promoting
communication and coordination between centers.
The expansion and coordination of existing par-
ticipant registries has been proposed as a method
to increase enrollment [11]. However this remains
a challenging task as registries can differ in scale
(multinational: European Prevention of Alzheimer’s
Consortium [EPAD], Global Alzheimer’s Platform
[GAP]; national: Alzheimer’s Prevention Registry,
Alzheimer Association’s TrialMatch; local institute-
specific registries at academic and research centers),
model (disease-specific versus general recruitment),
and type of data contained (contact information, med-
ical data) and little research is available for guidance
[36]. Besides increasing the quantity and speed of
recruitment, recently started multinational initiatives
such as EPAD and GAP will play a major role
in increasing sustainability of AD research. Tradi-
tionally, the majority of AD trials result from the
uncoordinated efforts of various private companies
and a considerable part of their huge costs can be
ascribed to the requirement of having to reconstruct
multiple resources for each trial. Costly tasks such
as creating registries, establishing the network of
sites and individual site preparation, preparing IRB
and other administrative documentation, establishing
evaluation and data collection protocols, and training
personnel are repeated for each trial. The purpose of
these initiatives is to build and maintain a structured
resource (by coordinating multinational registries)
that will allow continued access to patients and to
establish a harmonized trial protocol and network
of trial ready sites that will improve the logistical
burden, cost-efficiency, and comparability of future
research.
Education and advertising campaigns could be
effective for increasing awareness and improving atti-
tudes toward participation. Some research suggests
that investing in community-based education and out-
reach is more effective than educating primary care
providers [18, 25] and that direct mailings are more
effective than newspaper ads or community outreach
[26] but more research is clearly needed compar-
ing effectiveness of targeting different populations
(i.e., primary care doctors, residential homes inhab-
itants and staff, patient support groups, community
center members, or the general public) and using
different mediums or campaigns including lectures,
ground campaigns and pamphlets, and ads in news-
papers, radio, television, or internet. Planning and
executing these campaigns requires personnel and
resources typically available only to large centers.
For example, the NIA funded AD Research Centers
(ADRC) have education cores in charge of outreach
programing. Similarly, ACE counts with an outreach
team in charge of maintaining a website and monthly
electronic magazine, of interacting with social net-
works and the media (in 2016 the news generated
by ACE reached an estimated audience of more than
60 million people) and organizing community out-
reach activities (La Nit de l’Alzheimer [27], Regala
Memòria [28], Dia Mundial de l’Alzheimer) to raise
awareness. The expenses generated by the ACE out-
reach team account for about 4% of the total annual
expense. Activities such as the Open House Initiative
(OHI) [29], offering free cognitive evaluations once
a month (452 evaluations in 2016), the Estimul’Art
program [30], which organizes visits to art museums
for patients and families, diverse teaching and sup-
port activities [31], and publication of multiple books
and guides [32, 33] promoting age-specific AD edu-
cation and awareness are based on the principles of
“social responsibility” and “giving-first” that foster a
relationship of respect and trust with the community.
INCREASING PARTICIPANT RETENTION
Improving retention of study participants is a chal-
lenge of vital importance. Participant drop-out is a
key contributor to selection bias which poses a great
threat to the internal validity and generalizability of
results in clinical trials [4, 5]. More research analyz-
ing the reasons participants’ drop-out of AD trials and
evaluating different remedial strategies is urgently
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needed given the long follow-up periods required
for trials aimed at preventing progression or devel-
opment of cognitive impairment in MCI and healthy
populations respectively [44]. Analysis of one recent
trial in MCI with a 30% drop-out rate showed that
being non-white, not reaching university level educa-
tion, reporting greater depressive symptoms, having a
non-spousal study partner, and recruitment by a com-
mercial non-academic center were associated with
higher risk of drop-out [40]. A survey conducted by
the Center for Information and Study on Clinical
Research Participation [45] suggests that participants
who drop-out are more likely to report difficulty
understanding the consent form, un-satisfaction with
the answers to their questions in the consent form
interview, and described the site visits as “stressful.”
They were also less likely to report self-motivation
as the primary reason for participation.
The factors contributing to poor retention and the
strategies needed to address them partly overlap with
those pertaining to initial recruitment. In particular,
increasing outreach, education, or advertisements tar-
geting health care providers, patients, caregivers, and
the general public could help improve poor motiva-
tion and unfavorable attitudes towards research that
affect recruitment and retention alike. Targeting out-
reach and adapting trials to the needs of care-givers,
especially non-spousal care-givers, seems especially
important given that participants with non-spousal
study partners are less willing to participate [15]
and twice as likely to drop-out [40]. One study sug-
gests that reducing travel inconveniences, increasing
the probability of assignment to a treatment group,
and educating about the risks of participation could
increase care-givers willingness to participate [16].
Contrary to what some may expect, a recent review
reports that disease severity, trial length, or placebo
group placement did not clearly affect drop-out rate
[5] suggesting that other factors affecting partici-
pants’ subjective experience such as the quality of
care and the information received or the sense of pur-
pose, of being part of a larger enterprise, are more
important determinants of study completion. The
finding that subjects recruited by commercial centers
are twice as likely to drop-out also supports this idea
[40]. Interviews of AD research participants show
they value the access to diagnosis, care, emotional
support and up-to-date information about new treat-
ments [17] that come with participation in clinical
research. It follows that improving communication
and establishing a relationship of trust with patients
and care-givers is paramount to increase adherence.
Offering regular feedback via written reports or
personal meetings and organizing periodic research
participant gatherings are examples of activities that
could be implemented. Offering continued care, from
both clinical and social perspectives, instead of dis-
continuing visits in advanced stages of disease or at
the end of a trial is essential for participants to feel
supported instead of utilized. Furthermore, knowl-
edge of patients’ social circumstances and support
resources can help direct them to appropriate studies
and trials increasing the probability of study comple-
tion. Patients and families seek out and trust in ACE
because of this type of integrated care. At first visit,
every patient receives a clinical and social evaluation.
Follow-up medical (18,545 visits since 2013) and
social care (9,898 families evaluated and followed
up between 2006–2015) [46] is also always offered
and many patients (5,291 since 1991) participate in
day care and cognitive [47] stimulation programs.
ENSURING REPRESENTATIVENESS
OF THE RECRUITED SAMPLE
The recruited sample should be representative of
the general population presenting the studied condi-
tion to ensure external validity and generalizability
of trial results. However, this is usually not the case
in AD trials [24]. One of the main reasons is that
many trials exclude subjects with significant comor-
bidities or taking multiple medications making the
majority of AD patients followed in clinics ineli-
gible for trials [23, 24]. In our experience, around
10% of patients diagnosed with AD at ACE are eli-
gible for trials and the main reasons for exclusion
are advanced severity of disease, comorbidities, poly-
pharmacy, and absence of a study partner. It is also
well documented that research participants tend to
be of higher educational and socioeconomic levels
than the general population [48]. There are proba-
bly multiple interrelated causes of this phenomenon
including increased health awareness and confidence
in science and research institutions in individuals
of higher sociocultural levels. With respect to AD
research in particular, differences in conceptualiza-
tion and attitude towards the disease across different
social groups may also be a relevant factor [46].
It is noteworthy that ethnic and racial minorities
are systematically underrepresented in clinical tri-
als and observational studies. A 2007 review showed
that in the US only 3.2% of the subjects included
in clinical trials promoted by industry were non-
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white [49]. Possible causes are distrust toward the
medical establishment and research institutions, bar-
riers to access medical services, language barriers,
logistic and financial burden, lack of similarity and
cultural empathy between researchers and potential
participants [11, 50]. This over representation of
white participants supposes a dangerous bias for AD
research, especially since there is evidence showing
that minority groups could have increased risk of pre-
senting AD [51] and the US Census Bureau estimates
non-Hispanic whites will make up less than half of
the population by the year 2044 [52].
Different strategies have been proposed and tested
with the objective of recruiting representative sam-
ples for clinical trials and increasing research
participation in racial and ethnic minorities. Com-
munity outreach is a useful strategy in which direct
contact is established with a specific community
via alliances with its leaders or representative asso-
ciations. Inviting community leaders and members
to lectures or informative seminars regarding dis-
ease management and research opportunities are
usual practices. The concept of community based
participatory research (CBPR) defines a structured
and bidirectional methodology of community out-
reach that endeavors to reduce the distance between
researchers and a community by establishing a forum
of mutual communication and learning [53]. Investi-
gators inform of research results with the objective of
causing a positive impact in the health of the commu-
nity and so its members understand the importance
of scientific research and the principles it is based
on. Likewise, researchers receive feed-back from
community members regarding their preferences and
opinions as potential participants, allowing them to
adapt research methodology to “real world” commu-
nity needs. In this manner the community becomes
an active player in the research process and a relation-
ship of mutual trust is generated [54, 55]. Instead of
attributing the absence of individuals from a specific
community to their distrust of scientific and medical
institutions, this methodology helps scientists take an
active role in studying the role of the scientific com-
munity in creating and reducing this distrust. CBPR
methods have been used successfully for recruiting
minorities in AD research [56, 57]. For its success,
it is necessary that researchers establishing contact
understand specific aspects about the culture of the
community and maintain direct and stable contact
which typically requires research centers to desig-
nate personnel and resources specifically to outreach
activities. Promoting the “retooling” of staff scien-
tists to learn how to build community partnerships
could be an effective strategy for success of com-
munity outreach activities. Another strategy that has
also proved useful when combined with community
outreach methods [58, 59] involves concentrating
recruitment efforts on “satellite clinics” which pri-
marily attend minority populations generally due to
their geographical location.
THE BURDEN OF SCREEN FAILURES
Screening accuracy has profound effects on the
number of participants required and the cost and
length of recruitment. A failure in screening in AD
trials generally denotes a participant who does not
meet the inclusion/exclusion criteria after undergo-
ing lengthy (possibly >10 h) and expensive (>8000
US$ per subject) procedures including clinical and
cognitive evaluations, blood and CSF analysis, and
MRI and PET brain scans. Screen failure rate has
been worryingly high in AD trials and inclusion of
subjects without AD is often cited as one of the main
reasons of failed trials in the past [60]. The introduc-
tion of AD biomarker inclusion criteria has helped
identify subjects with putative AD; however, it has
introduced the new problem of predicting which sub-
jects will be amyloid PET or CSF positive and screen
failure rate has sky rocketed to 70–90% in recent trials
of prodromal AD (MCI with positive AD biomarkers)
[61]. The younger age of participants in preven-
tion trials comes with lower prevalence of some
causes of screen failure such as co-morbidity and
poly-pharmacy however the probability of biomarker
positivity indicating brain amyloidosis is also lower
making the reduction of screen failure rate an even
greater challenge in trials of preclinical AD (cogni-
tively intact subjects with positive AD biomarkers).
Improving screening accuracy starts early in
the trial design phase. The selection of inclu-
sion/exclusion criteria requires substantial prior
knowledge and planning to identify a target popu-
lation which is feasible to recruit with the available
resources. The ability to perform accurate and reli-
able clinical diagnoses is also essential to reduce
screen failures and crucially depends on the avail-
ability of appropriate diagnostic tests and clinical
expertise in the recruiting center. Recruiting from the
same center where patients are diagnosed and fol-
lowed entails that the same team of expert clinicians
is involved or at least in frequent and close communi-
cation with the professionals in charge of recruiting.
M. Boada et al. / Patient Engagement: The Fundació ACE Model 1085
Active participation in basic and clinical research pro-
grams and longitudinal studies adds further expertise
that benefits screening accuracy. The use of sample
enrichment and targeted clinical trial designs hold
great potential for reducing recruitment requirements
by increasing the power of finding treatment effects in
heterogeneous conditions such as AD [12, 62]. These
techniques are based on the idea that the treatment
under study might benefit a subset of patients in the
population in particular [63]. In AD trials this may
entail enriching a MCI sample with subjects that are
likely to show early significant decline or random-
izing only subjects with positive brain amyloidosis
biomarkers to receive an anti-amyloid medication.
Since these techniques rely critically on the challeng-
ing task of reliably identifying a subset of patients,
errors in implementation can result in elevated rates
of screening failure. This is yet another reason that
supports concentrating recruitment activity in com-
prehensive AD centers that run basic and clinical
research programs besides offering diagnosis and
continued care. For example, by developing its own
neuropsychological battery and normative data that
allow calculation of sensitivity and specificity for
detecting dementia [64], ACE is able to identify a
subset of MCI in which 70% of subjects convert to
dementia in less than 2 years [65]. Similarly, active
genetic [66], CSF biomarker, neuroimaging [67, 68],
and longitudinal aging [69] research programs pro-
vide the tools and knowledge of how to classify
patients according to genetic, CSF, neuroimaging,
and clinical features and contribute to the low screen
failure rate at ACE (72 out of 384 patients, 19%, in
2016).
IMPLICATIONS OF RECRUITING FOR
PREVENTION TRIALS
Preventive clinical trials are gaining importance as
the scientific community realizes it may be necessary
to intervene at earlier stages of AD for treatments to
be effective [70]. Different levels of prevention have
been defined in the context of the establishment of
preclinical AD as a nosologic entity [71]. Primary
prevention targets healthy subjects with the objective
of preventing the biologic processes associated with
the disease whereas secondary prevention is directed
at cognitively intact subjects that present preclinical
AD [72], which refers to biologic evidence of AD in
the form of deterministic genes or positive biomark-
ers. Primary and secondary prevention trials present
many common features but there are also important
differences that can affect recruitment.
A common feature is that the target population
of preventive trials is generally not found in the
usual clinical settings. Cognitively intact individu-
als typically make up only a small proportion of the
population attended by memory clinics. These indi-
viduals are generally younger than those with MCI
or dementia and are usually active members of the
workforce with little availability for multiple visits
and medical procedures. Another common feature is
that the probability of short term cognitive decline is
lower in this population requiring an elevated num-
ber of participants or longer follow-up periods to
ensure enough power to detect statistically signif-
icant treatment effects [73]. Sample size and trial
length are especially large in primary prevention trials
[74, 75] because, in the absence of biologic evidence
of AD, the expected rate of progression is similar to
that of the general population. In this case, an often
employed strategy is “enrichment” of the sample with
AD risk factors such as older age [76], APOE carri-
ers [77], or other modifiable risk factors [78]. Though
the expected rate of progression is faster, secondary
prevention trials present their own significant logistic
and ethical challenges [79]. In this case, cognitively
intact individuals are told they have an increased risk
of developing cognitive impairment and dementia
(possibly without a clear time-frame) and are offered
to participate in a complex trial consisting of multiple
time-consuming visits, medical procedures which are
not always innocuous, and exposure to an experimen-
tal treatment. All of these circumstances complicate
the recruitment process. In our experience at ACE, the
time necessary for informed consent is significantly
longer and the proportion of individuals who decline
trial participation is much higher than in MCI or AD
trials. Adding positive biomarkers to inclusion crite-
ria also complicates recruitment. Biomarker analysis
is not part of the typical work up in cognitively intact
subjects and predicting a positive result based on clin-
ical evaluation is very challenging which can lead to
high screen failure rate due to biomarker negativity
[36].
These difficulties related to recruiting for AD pre-
vention trials necessitate far-reaching strategies that
act upon multiple levels to engage a primarily non-
memory clinic population [73]. Large informative
campaigns directed at the general public explaining
the urgency of halting AD’s epidemic progression
and of the importance of research to succeed in this
enormous challenge. The global society needs to
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understand that dementia and AD are partially pre-
ventable by intervening upon modifiable risk factors
and that these conditions begin with a long preclini-
cal stage in which interventions are potentially more
effective. In this manner it is foreseeable that the num-
ber of asymptomatic people who decide to undergo a
“cognitive check-up” and enroll in research programs
will grow.
Memory clinics can implement certain initiatives
with the objective of facilitating the arrival of cog-
nitively intact individuals. Since 2008, ACE carries
out an Open House Initiative (OHI) as part of its cor-
porate social responsibility program in which a local
publicity campaign invites anybody over the age of 50
to come to the memory clinic for a “cognitive check-
up” free of charge and without the requirement of
being referred by another medical professional [37].
Subjects meeting inclusion criteria for any ongo-
ing research studies are invited to participate on
a later date. Since its start, the OHI has attracted
almost two-thousand (approximately 300 in 2016)
cognitively intact individuals which would proba-
bly not have come to the memory clinic otherwise
and many of these individuals have enrolled in clin-
ical trials or observational studies [69]. On average,
each evaluation includes 40 minutes of a neurolo-
gist or neuropsychologist’s time for performing the
cognitive evaluation, 20 minutes of administrative
paperwork, and 15 minutes of nurse-time. It is of
note that the setting and mode of recruitment can
affect sample characteristics. There is evidence show-
ing that cognitively intact subjects recruited from
memory clinics show higher rates of AD biomarker
positivity than those recruited from the community
[39, 80]. Thus recruiting from non-memory clinic
settings gives access to a larger pool of potential
participants but may result in lower prevalence of
positive AD biomarkers and higher rates of screen
failure [37].
Registries of cognitively healthy individuals who
are potentially willing to participate in research
studies could be a valid source of participants for pre-
ventive clinical trials. Proper coordination between
multiple registries and a network of centers that are
geographically close to potential participants and
offer the possibility of participation is necessary to
maximize efficiency of this strategy [55]. However,
in the case of secondary prevention trials that require
positive biomarkers, most subjects in the registry
would probably not be eligible and many may not
accept enrollment into a trial of an experimental drug.
In this case, an intermediate option that could facili-
tate recruitment of individuals with preclinical AD is
the existence of observational cohorts with available
biomarker data in which participants are asked upon
entry about their willingness to enroll in clinical trials
in the case of biomarker positivity and the consequent
increased risk of developing cognitive impairment
[81].
CONCLUSION
The goal of this article was to highlight the critical
role of patient engagement in the challenge of devel-
oping treatment and prevention strategies for AD.
We outlined specific problems and discussed vari-
ous remedial strategies that can be implemented by
comprehensive AD centers. To increase the pool of
potential participants we considered the possibility of
expansion of recruiting sites, coordination of partic-
ipant registries, coordination with primary care and
other local medical centers, and increasing awareness
and improving the general public’s attitude towards
participation in research through advertisement and
outreach. Targeting outreach and adapting trials to
the needs of caregivers, improving communication
and offering regular feedback, and building a rela-
tionship of trust through continued clinical and social
care could improve participant retention in trials
and longitudinal studies. Implementation of commu-
nity based participatory research methodology could
help improve diversity and representativeness of the
recruited sample with respect to “real-world” AD
patients in the population. Focusing recruitment in
the same centers that diagnose and follow patients and
that participate in research helps guarantee availabil-
ity of the clinical expertise and technical resources
that are necessary to reduce screening failure rate.
Finally, specific challenges relating to recruitment in
the preclinical AD population were discussed.
Recruitment and retention is increasingly recog-
nized as one of the most important rate limiting
factors delaying therapy development and key stake-
holders in AD research world-wide are designing
work groups and action plans to address this urgent
difficulty. We provided an overview of specific dif-
ficulties related to patient recruitment and retention
and strategies to address these problems drawing
from our experience at ACE. There is an urgent
need for research studying the applicability and
cost-effectiveness of different recruitment strategies
across different settings and nationalities. In this line,
we described the Models of Patient Engagement for
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Alzheimer’s Disease (MOPEAD) project which will
provide a large multinational quantitative analysis
comparing different innovative recruitment models.
The specific methods and organization of ACE are
likely not generalizable to all parts the world, however
the success of ACE shows that a model of integrated
clinical and social patient-centered care with a built-
in research emphasis and an active outreach team can
effectively implement strategies that increase patient
engagement in the local community.
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